For Q1 FY2026 ended March 31, 2026, Delcath Systems reported revenue of $24.99 million, up 26.3% year-over-year. Net loss was $1.07 million, compared to net income of $1.07 million in the prior year. Operating loss was $1.64 million, and diluted EPS was -$0.03. Cash and cash equivalents stood at $41.31 million, with total equity of $112.71 million.
•Revenue grew 26.3% YoY to $24.99 million.
•Net loss of $1.07 million vs. net income of $1.07 million a year ago.
•Operating loss widened to $1.64 million.
•Cash and equivalents of $41.31 million; no long-term debt reported.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Delcath Systems, Inc., an interventional oncology company focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma
HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Founded in 1988, the company is headquartered in Queensbury, New York.
Delcath Systems, Inc. is an interventional oncology company focused on treating primary and metastatic liver cancers. Its lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system that administers high-dose chemotherapy directly to the liver while minimizing systemic exposure and side effects. The company is also conducting the FOCUS clinical trial to evaluate HEPZATO in patients with metastatic hepatic dominant uveal melanoma, measuring objective response rates. In Europe, Delcath markets the CHEMOSAT Hepatic Delivery System, a stand-alone medical device used for melphalan delivery to treat various liver cancers. The company operates in both the United States and Europe, targeting a significant unmet need in liver cancer treatment.
Where is Delcath Systems (DCTH) listed and what currency does it trade in?
Delcath Systems, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol DCTH. Its shares are traded in U.S. dollars (USD), reflecting its primary listing in the United States. The NasdaqCM is a U.S.-based stock exchange that typically hosts smaller-cap companies, and Delcath's listing there provides liquidity and visibility to investors interested in the healthcare and medical device sectors.
What sector and industry does Delcath Systems (DCTH) belong to?
Delcath Systems operates in the Healthcare sector and is classified under the Medical Devices industry. This means the company develops and commercializes medical devices and related therapies, specifically focusing on interventional oncology—a field that uses minimally invasive procedures to treat cancer. Its products, such as the HEPZATO KIT and CHEMOSAT system, are categorized as medical devices that deliver chemotherapy directly to liver tumors, combining device technology with pharmaceutical agents.
Where is Delcath Systems headquartered and what markets does it serve?
Delcath Systems, Inc. is headquartered in Queensbury, New York, United States. The company serves both the U.S. and European markets. In the United States, its lead product candidate HEPZATO KIT is under clinical investigation, while in Europe, the CHEMOSAT Hepatic Delivery System is commercially available for medical centers to treat a range of liver cancers. This dual-market strategy allows Delcath to address liver cancer patients across different regulatory environments.
What is Delcath Systems' business model and how does it generate revenue?
Delcath Systems generates revenue primarily through the commercialization of its interventional oncology products. In Europe, the company sells the CHEMOSAT Hepatic Delivery System as a stand-alone medical device, which hospitals and clinics purchase to administer melphalan chemotherapy for liver cancer treatments. In the United States, Delcath is pursuing regulatory approval for HEPZATO KIT, and upon approval, it would generate revenue from sales of the combined drug-device product. The company also conducts clinical trials, such as the FOCUS trial, to expand indications and support product adoption. Revenue is derived from product sales and potentially from licensing or partnerships.